Concepts (226)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Juvenile | 11 | 2024 | 33 | 1.950 |
Why?
|
| Lupus Erythematosus, Systemic | 15 | 2022 | 211 | 1.420 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2019 | 65 | 1.180 |
Why?
|
| Rheumatic Diseases | 3 | 2017 | 26 | 1.040 |
Why?
|
| Antirheumatic Agents | 7 | 2024 | 58 | 1.000 |
Why?
|
| Granulomatosis with Polyangiitis | 3 | 2024 | 10 | 0.950 |
Why?
|
| Rheumatology | 3 | 2022 | 35 | 0.780 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2021 | 19 | 0.750 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2019 | 27 | 0.670 |
Why?
|
| Catatonia | 1 | 2019 | 9 | 0.640 |
Why?
|
| Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2019 | 8 | 0.640 |
Why?
|
| Electroconvulsive Therapy | 1 | 2019 | 25 | 0.630 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 243 | 0.610 |
Why?
|
| Aspirin | 1 | 2019 | 162 | 0.610 |
Why?
|
| Immunologic Factors | 1 | 2019 | 170 | 0.600 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 3 | 2024 | 8 | 0.590 |
Why?
|
| Macrophage Activation Syndrome | 1 | 2015 | 2 | 0.500 |
Why?
|
| Antibodies, Antinuclear | 1 | 2015 | 85 | 0.490 |
Why?
|
| Child | 25 | 2024 | 7194 | 0.480 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2015 | 323 | 0.470 |
Why?
|
| Immunosuppressive Agents | 6 | 2024 | 981 | 0.440 |
Why?
|
| Adolescent | 19 | 2024 | 9312 | 0.440 |
Why?
|
| Cyclophosphamide | 4 | 2024 | 300 | 0.430 |
Why?
|
| Pyrroles | 3 | 2024 | 172 | 0.410 |
Why?
|
| Microscopic Polyangiitis | 3 | 2024 | 3 | 0.400 |
Why?
|
| Glucocorticoids | 3 | 2018 | 359 | 0.330 |
Why?
|
| Female | 26 | 2024 | 46612 | 0.270 |
Why?
|
| Rituximab | 2 | 2024 | 118 | 0.260 |
Why?
|
| Lupus Nephritis | 3 | 2018 | 77 | 0.260 |
Why?
|
| Humans | 37 | 2024 | 90005 | 0.250 |
Why?
|
| Arthralgia | 2 | 2015 | 40 | 0.240 |
Why?
|
| Mycophenolic Acid | 3 | 2022 | 84 | 0.240 |
Why?
|
| Registries | 4 | 2024 | 809 | 0.230 |
Why?
|
| Atherosclerosis | 3 | 2013 | 260 | 0.230 |
Why?
|
| Piperidines | 1 | 2024 | 163 | 0.220 |
Why?
|
| Treatment Outcome | 10 | 2024 | 8312 | 0.210 |
Why?
|
| Connective Tissue Diseases | 1 | 2023 | 70 | 0.210 |
Why?
|
| Pharmaceutical Services | 1 | 2022 | 9 | 0.200 |
Why?
|
| Heptanoic Acids | 2 | 2013 | 71 | 0.200 |
Why?
|
| Induction Chemotherapy | 2 | 2024 | 153 | 0.200 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2002 | 76 | 0.200 |
Why?
|
| Pyrimidines | 1 | 2024 | 371 | 0.190 |
Why?
|
| Child, Preschool | 8 | 2024 | 3759 | 0.190 |
Why?
|
| Skin Ulcer | 1 | 2021 | 25 | 0.190 |
Why?
|
| Pediatrics | 3 | 2017 | 358 | 0.180 |
Why?
|
| Abatacept | 1 | 2021 | 86 | 0.180 |
Why?
|
| Withholding Treatment | 2 | 2019 | 115 | 0.180 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2001 | 55 | 0.180 |
Why?
|
| DNA, Viral | 1 | 2001 | 263 | 0.170 |
Why?
|
| Saliva | 1 | 2001 | 124 | 0.170 |
Why?
|
| Remission Induction | 3 | 2024 | 742 | 0.170 |
Why?
|
| Drug Therapy, Combination | 3 | 2018 | 786 | 0.170 |
Why?
|
| S100A12 Protein | 1 | 2019 | 10 | 0.160 |
Why?
|
| Calgranulin A | 1 | 2019 | 11 | 0.160 |
Why?
|
| Calgranulin B | 1 | 2019 | 15 | 0.160 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 2 | 2009 | 7 | 0.160 |
Why?
|
| Benzodiazepines | 1 | 2019 | 69 | 0.160 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2011 | 2417 | 0.150 |
Why?
|
| Methotrexate | 4 | 2021 | 243 | 0.150 |
Why?
|
| Male | 19 | 2024 | 42706 | 0.150 |
Why?
|
| Infant | 3 | 2019 | 3178 | 0.150 |
Why?
|
| Prednisone | 3 | 2015 | 253 | 0.140 |
Why?
|
| Guideline Adherence | 1 | 2018 | 232 | 0.140 |
Why?
|
| Nephrotic Syndrome | 1 | 2016 | 33 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2011 | 2360 | 0.130 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2015 | 12 | 0.130 |
Why?
|
| C-Reactive Protein | 2 | 2013 | 193 | 0.120 |
Why?
|
| Respiratory Insufficiency | 1 | 2016 | 162 | 0.120 |
Why?
|
| Calcitonin | 1 | 2014 | 38 | 0.120 |
Why?
|
| Hemorrhage | 1 | 2016 | 287 | 0.120 |
Why?
|
| Cyclosporine | 1 | 2015 | 238 | 0.120 |
Why?
|
| Diphosphonates | 1 | 2014 | 33 | 0.120 |
Why?
|
| Lung Diseases | 1 | 2016 | 275 | 0.110 |
Why?
|
| Knee Joint | 1 | 2015 | 167 | 0.110 |
Why?
|
| Bone Density | 1 | 2014 | 211 | 0.110 |
Why?
|
| Osteoporosis | 1 | 2014 | 122 | 0.110 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2013 | 47 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 537 | 0.100 |
Why?
|
| Kidney Failure, Chronic | 1 | 2016 | 415 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 603 | 0.100 |
Why?
|
| Vitamin D | 1 | 2014 | 269 | 0.100 |
Why?
|
| Risk Factors | 7 | 2023 | 5551 | 0.100 |
Why?
|
| Biomarkers | 3 | 2019 | 1782 | 0.100 |
Why?
|
| Disease Progression | 4 | 2023 | 1475 | 0.100 |
Why?
|
| Intracranial Aneurysm | 1 | 2013 | 178 | 0.090 |
Why?
|
| NADPH Oxidases | 1 | 2011 | 82 | 0.090 |
Why?
|
| Multiprotein Complexes | 1 | 2011 | 96 | 0.090 |
Why?
|
| Cohort Studies | 4 | 2024 | 2877 | 0.090 |
Why?
|
| Anticholesteremic Agents | 1 | 2012 | 141 | 0.090 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 2 | 2022 | 21 | 0.080 |
Why?
|
| STAT4 Transcription Factor | 1 | 2009 | 10 | 0.080 |
Why?
|
| Carotid Artery, Common | 1 | 2009 | 28 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 377 | 0.080 |
Why?
|
| Tunica Intima | 1 | 2009 | 60 | 0.080 |
Why?
|
| Symptom Flare Up | 2 | 2019 | 12 | 0.080 |
Why?
|
| Age of Onset | 2 | 2024 | 317 | 0.080 |
Why?
|
| Selenoprotein P | 1 | 2007 | 1 | 0.080 |
Why?
|
| Musculoskeletal Diseases | 1 | 2008 | 33 | 0.070 |
Why?
|
| Models, Molecular | 1 | 2011 | 1315 | 0.070 |
Why?
|
| Prospective Studies | 4 | 2018 | 4333 | 0.070 |
Why?
|
| Proteoglycans | 1 | 1986 | 123 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 693 | 0.060 |
Why?
|
| Neutrophils | 1 | 1986 | 312 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2019 | 700 | 0.060 |
Why?
|
| Genetic Variation | 1 | 2011 | 1380 | 0.060 |
Why?
|
| Herpes Zoster | 1 | 2024 | 79 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2010 | 715 | 0.060 |
Why?
|
| Double-Blind Method | 3 | 2013 | 1713 | 0.050 |
Why?
|
| Azathioprine | 2 | 2016 | 124 | 0.050 |
Why?
|
| Brain | 1 | 2013 | 2311 | 0.050 |
Why?
|
| Carotid Intima-Media Thickness | 2 | 2013 | 39 | 0.050 |
Why?
|
| Young Adult | 4 | 2022 | 6374 | 0.050 |
Why?
|
| Neoplasms | 1 | 2017 | 3011 | 0.050 |
Why?
|
| Disability Evaluation | 1 | 2003 | 140 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2024 | 1870 | 0.050 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 2000 | 18 | 0.050 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2001 | 40 | 0.050 |
Why?
|
| Medication Adherence | 1 | 2022 | 138 | 0.040 |
Why?
|
| Health Status | 1 | 2003 | 370 | 0.040 |
Why?
|
| Time Factors | 3 | 2019 | 5353 | 0.040 |
Why?
|
| Sex Factors | 2 | 2017 | 1073 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2024 | 587 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2023 | 736 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2016 | 274 | 0.040 |
Why?
|
| Quality of Life | 1 | 2008 | 1678 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2001 | 311 | 0.040 |
Why?
|
| Life Tables | 1 | 2018 | 47 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2001 | 919 | 0.040 |
Why?
|
| Maintenance Chemotherapy | 1 | 2019 | 84 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2000 | 320 | 0.040 |
Why?
|
| Echocardiography | 1 | 2023 | 943 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2002 | 1605 | 0.040 |
Why?
|
| Rheumatologists | 1 | 2017 | 6 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2018 | 873 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2022 | 2652 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2014 | 1725 | 0.030 |
Why?
|
| Haplotypes | 2 | 2009 | 638 | 0.030 |
Why?
|
| Plasmapheresis | 1 | 2016 | 25 | 0.030 |
Why?
|
| United States | 3 | 2016 | 7097 | 0.030 |
Why?
|
| Bayes Theorem | 2 | 2009 | 382 | 0.030 |
Why?
|
| Asia | 1 | 2016 | 102 | 0.030 |
Why?
|
| Health Surveys | 1 | 2017 | 239 | 0.030 |
Why?
|
| Consensus | 1 | 2018 | 369 | 0.030 |
Why?
|
| Proteinuria | 1 | 2016 | 67 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2017 | 159 | 0.030 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2016 | 60 | 0.030 |
Why?
|
| Age Distribution | 1 | 2016 | 198 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2018 | 788 | 0.030 |
Why?
|
| Canada | 1 | 2016 | 201 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 840 | 0.030 |
Why?
|
| Europe | 1 | 2016 | 324 | 0.030 |
Why?
|
| Genotype | 2 | 2011 | 1854 | 0.030 |
Why?
|
| Bone Density Conservation Agents | 1 | 2014 | 42 | 0.030 |
Why?
|
| Absorptiometry, Photon | 1 | 2014 | 102 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2016 | 338 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 954 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2014 | 279 | 0.030 |
Why?
|
| Kidney | 1 | 2018 | 1148 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2014 | 159 | 0.030 |
Why?
|
| Incidence | 1 | 2017 | 1589 | 0.030 |
Why?
|
| Puberty | 1 | 2013 | 60 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2013 | 296 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-vav | 1 | 2011 | 10 | 0.020 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2011 | 48 | 0.020 |
Why?
|
| Carotid Arteries | 1 | 2013 | 135 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2013 | 226 | 0.020 |
Why?
|
| California | 1 | 2011 | 146 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2011 | 161 | 0.020 |
Why?
|
| Plasmids | 1 | 2011 | 291 | 0.020 |
Why?
|
| Radiography | 1 | 2013 | 809 | 0.020 |
Why?
|
| Lipoprotein(a) | 1 | 2010 | 30 | 0.020 |
Why?
|
| Lipoproteins, LDL | 1 | 2010 | 85 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 3681 | 0.020 |
Why?
|
| Placebos | 1 | 2010 | 211 | 0.020 |
Why?
|
| Lipoproteins, HDL | 1 | 2010 | 97 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2011 | 281 | 0.020 |
Why?
|
| Lipids | 1 | 2012 | 275 | 0.020 |
Why?
|
| Triglycerides | 1 | 2010 | 233 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2023 | 9243 | 0.020 |
Why?
|
| STAT1 Transcription Factor | 1 | 2009 | 53 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2011 | 491 | 0.020 |
Why?
|
| Lipoproteins | 1 | 2009 | 136 | 0.020 |
Why?
|
| Cholesterol | 1 | 2010 | 360 | 0.020 |
Why?
|
| Creatinine | 1 | 2009 | 294 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 1867 | 0.020 |
Why?
|
| Microchip Analytical Procedures | 1 | 2007 | 3 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2011 | 2064 | 0.020 |
Why?
|
| Protein Binding | 1 | 2011 | 1492 | 0.020 |
Why?
|
| Autoantibodies | 1 | 2009 | 272 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 3024 | 0.020 |
Why?
|
| Zymosan | 1 | 1986 | 6 | 0.020 |
Why?
|
| Chondroitinases and Chondroitin Lyases | 1 | 1986 | 8 | 0.020 |
Why?
|
| Glycosides | 1 | 1986 | 20 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 1986 | 81 | 0.020 |
Why?
|
| Sulfates | 1 | 1986 | 57 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2009 | 720 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2007 | 477 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2009 | 774 | 0.020 |
Why?
|
| Leukocytes | 1 | 1986 | 209 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 1580 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2009 | 1869 | 0.010 |
Why?
|
| Computational Biology | 1 | 2007 | 551 | 0.010 |
Why?
|
| Staphylococcus aureus | 1 | 1986 | 278 | 0.010 |
Why?
|
| Joints | 1 | 2003 | 33 | 0.010 |
Why?
|
| Injections, Intra-Articular | 1 | 2003 | 31 | 0.010 |
Why?
|
| Uveitis | 1 | 2003 | 31 | 0.010 |
Why?
|
| Phenotype | 1 | 2009 | 2460 | 0.010 |
Why?
|
| Educational Status | 1 | 2003 | 194 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2003 | 206 | 0.010 |
Why?
|
| Adult | 1 | 2001 | 26811 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1986 | 2887 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2009 | 1692 | 0.010 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2000 | 36 | 0.010 |
Why?
|
| Celecoxib | 1 | 2000 | 31 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2000 | 99 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2000 | 274 | 0.010 |
Why?
|
| Pyrazoles | 1 | 2000 | 151 | 0.010 |
Why?
|
| Mice | 1 | 2009 | 11869 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2000 | 1227 | 0.010 |
Why?
|
| Arthrography | 1 | 1993 | 8 | 0.010 |
Why?
|
| Carpal Bones | 1 | 1993 | 12 | 0.010 |
Why?
|
| Wrist Joint | 1 | 1993 | 24 | 0.010 |
Why?
|
| Movement | 1 | 1993 | 313 | 0.010 |
Why?
|
| Animals | 1 | 2009 | 27548 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 1989 | 166 | 0.000 |
Why?
|
| Infusions, Intravenous | 1 | 1989 | 416 | 0.000 |
Why?
|